Oral physiological magnesium supplementation for 6 weeks with 1 g/d magnesium oxide does not affect increased Lp(a) levels in hypercholesterolaemic subjects

Magnesium Research

Volumn 9, Issue 2, 1996, Pages 129-131

  Hoogerbrugge, Nicoline ^a   Cobbaert, Christa ^a   De Heide, Loek ^a   Birkenhäger, Jan C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cholesterol; Lipoprotein (a); Magnesium

Indexed keywords

APOLIPOPROTEIN A; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MAGNESIUM; MAGNESIUM OXIDE; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY;

ADMINISTRATION, ORAL; APOLIPOPROTEINS A; CHOLESTEROL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MAGNESIUM; MAGNESIUM OXIDE; MALE; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 0030155074     PISSN: 09531424     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Davis, W.H., Leary, W.P. & Reyes A.J. (1984): Monotherapy with magnesium increases abnormally low high density lipoprotein cholesterol: a clinical assay. Curr. Ther. Res. 36, 341-345.
2. Marken, P.A., Weart, C.W., Carson, D.S., Gums, J.G. & Lopes-Virella, M.F. (1989): Effects of magnesium on the lipid profile of healthy volunteers. Atherosclerosis 77, 37-42.
3. Sperber, A.D., Henkin, Y., Zuili, I., Bearman, J. & Shany, S. (1991): The hypocholesterolemic effect of an antiacid containing aluminum hydroxide. Am. J. Med. 91, 597-604.
4. Kisters, K., Spieker, C., Tepel, M. & Zidek, W. (1993): New data about the effects of oral physiological magnesium supplementation on several cardiovascular risk factors (lipid and blood pressure). Magnes. Res. 6, 355-60.
5. Witteman, J.C.M., Grobbee, D.E., Derkx, F.H.M., Bouillon, R., de Bruyn, A.M. & Hofman, A. (1994): Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension. Am. J. Clin. Nutr. 60, 129-135.
6. Kostner, G.M. (1988): The effects of lipoprotein (a) by lipid-lowering drugs. Recent aspects of diagnosis and treatment of lipoprotein disorders. In: Impact on prevention of atherosclerotic disease, pp. 255-263. New York: Alan R. Liss.
7. Loscalzo, J. (1990): Lipoprotein (a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 10, 672-679.
8. Itoh, K., Kawasaki, T., Yoshida, H. & Nakamura, M. (1994): Effects of oral magnesium supplementation on blood pressure, serum lipids and urinary catecholamines in healthy young subjects. J. Hypertens. 12 (S3), abstract 480.
9. Moorkens, G., Bouten, A., Vertommen, J. & De Leeuw, I. (1995): No corelation can be found between raised levels of Lp(a) and magnesium depletion in insulin-dependent diabetic patients. Magnes. Res. 8, suppl 1, 55-56.
10. Friedewald, W.T., Levy, R.I. & Fredrickson, D.S. (1972): Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifugation. Clin. Chem. 18, 499-502.
11. Durlach, J., Durlach, V., Bac, P., Bara, M. & Guiet-Bara, A. (1994): Magnesium and therapeutics. Magnes. Res. 7, 313-328.
12. Rayssiguier, Y., Mazur, A., Cardot, P. & Gueux E. (1989) In: Magnesium in health and disease, eds. Y. Itokawa & J. Durlach, pp. 199-207. London: John Libbey.